Biologics CDMO Market Report and Forecast 2025-2034
Description
The global biologics CDMO market was valued at USD 17.84 Billion in 2024, driven by the rising incidence of chronic diseases across the globe. The market is anticipated to grow at a CAGR of 10.80% during the forecast period of 2025-2034, with the values likely to reach USD 49.75 Billion by 2034.
Biologics CDMO Market Overview
Biologic contract development and manufacturing organisations (CDMOs) are specialised companies that provide outsourced services for the development and manufacturing of biologic drugs. These organisations support pharmaceutical and biotechnology companies in the production of biologics, which are complex molecules derived from living organisms, such as monoclonal antibodies, vaccines, cell and gene therapies, and recombinant proteins.
Biologics CDMO Market Growth Drivers
Advancements in Biologics Manufacturing Drive Global Market Expansion
The rising demand for biologics and the need for robust manufacturing infrastructure are key drivers of the market. In September 2024, Eurofins CDMO Alphora announced its plans to build a GMP biologics manufacturing facility in Mississauga, Canada, supported by federal funding and the Strategic Initiative Fund. This facility aims to enhance Canada's capacity for producing monoclonal antibodies and protein therapies for clinical and commercial use. The investment is poised to strengthen the global brain-computer interface (BCI) market by ensuring a stable supply of biologics critical for therapeutic BCI applications, enabling innovation and expanding accessibility during the forecast period.
New Biologics CDMO Ventures to Meet Biologics CDMO Market Demand
The growing demand for plasmid DNA in gene therapies and advanced biologics is shaping the CDMO market. In June 2024, Asahi Kasei Medical’s subsidiary, Bionova Scientific, announced its expansion into plasmid DNA services, establishing a dedicated facility in Texas, USA. This move aligns with the rising demand for biologics CDMOs offering specialised services. The initiative is expected to accelerate the global BCI market growth by enabling the development of cutting-edge therapies that utilise plasmid DNA, fostering innovation in neurotechnology solutions and facilitating their integration into clinical and commercial applications over the forecast period.
Biologics CDMO Market Trends
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
Rapid Expansion Driven by Rising Biologics Demand Globally
The surge in biologics development, including monoclonal antibodies and gene therapies, is driving pharmaceutical companies to outsource production to CDMOs. This trend allows companies to focus on R&D while leveraging CDMOs’ specialised capabilities, boosting market growth.
Technological Advancements Shaping Market Landscape
CDMOs are increasingly adopting single-use bioreactors and other disposable technologies to enhance production flexibility and scalability. For instance, in October 2024, Samsung Biologics, a leading contract development and manufacturing organisation (CDMO), launched a new high-concentration formulation platform, S-HiCon. This platform is designed to enhance the stability and efficacy of high-dose biopharmaceuticals, which is crucial for biologics manufacturing. Samsung Biologics is advancing its capabilities in biologics formulation, which will drive further growth in the CDMO market by supporting the development of more complex biologic drugs and ensuring their effective delivery. These innovations reduce contamination risks, improve efficiency, and cater to the needs of small and mid-scale biologics manufacturers, accelerating market development.
Investments and Facilities Expansion Elevate Biologics CDMO Market Value
Major players are making substantial investments in new manufacturing facilities to meet rising biologics demand. These expansions, particularly in emerging regions, are boosting production capacity and market value, offering tailored solutions to biopharma companies globally.
Strategic Collaborations and Regional Growth Transform CDMO Opportunities
The Asia-Pacific region is becoming a hub for biologics CDMO services, driven by lower production costs, government incentives, and growing biopharmaceutical activity. CDMOs are capitalising on this trend by establishing advanced facilities to cater to global clients.
Biologics CDMO Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Monoclonal Antibodies Dominate Biologics CDMO Market Share Growth
The monoclonal antibodies (mAbs) segment dominates the market share by product type due to their widespread use in treating cancer, autoimmune diseases, and infectious diseases. As per the Expert Market Research analysis, the global monoclonal antibodies market is expected to grow at a CAGR of 11.5% during the forecast period of 2025-2034. Increasing demand for targeted therapies, advancements in antibody engineering, and rising approvals for biosimilar mAbs are key drivers. This segment’s robust growth potential ensures its continued market leadership, significantly driving biologics CDMO market expansion during the forecast period through innovation and scalability in production.
Biologics CDMO Market Analysis by Region
North America dominates the market due to advanced healthcare infrastructure, significant investments in biologics manufacturing, and strong R&D activity. The region benefits from a robust pharmaceutical ecosystem, regulatory support, and a focus on innovative therapies such as cell and gene therapies. Future growth is driven by rising demand for biologics and increasing outsourcing trends, positioning North America to sustain market leadership during the forecast period.
Leading Players in the Biologics CDMO Market
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Boehringer Ingelheim Group
Established in 1885 and headquartered in Ingelheim, Germany, Boehringer Ingelheim is a leading pharmaceutical company. In the biologics CDMO sector, it offers comprehensive services, including cell line development, process development, and large-scale manufacturing of therapeutic proteins and antibodies.
Wuxi Biologics (Cayman) Inc
Founded in 2010 and based in Wuxi, China, WuXi Biologics is a prominent biologics CDMO. It provides end-to-end solutions, encompassing discovery, development, and manufacturing services for biologics, including monoclonal antibodies, bispecifics, and recombinant proteins.
Samsung Biologics Co., Ltd
Established in 2011 and headquartered in Songdo, Incheon, South Korea, Samsung Biologics is a global CDMO. Its portfolio includes contract development, manufacturing, and laboratory testing services for biopharmaceutical products, focusing on monoclonal antibodies and biosimilars.
Lonza Group Ltd
Founded in 1897 and based in Basel, Switzerland, Lonza is a multinational company serving the pharmaceutical and biotechnology sectors. In the biologics CDMO market, it offers services such as cell line development, process optimisation, and large-scale manufacturing of biologics, including antibodies and cell therapies.
Other key players in the market include Fujifilm Diosynth Biotechnologies Inc., Toyobo Co. Ltd., Binex Co. Ltd, The Celonic Group, Rentschler Biopharma SE, and AGC Biologics.
Key Questions Answered in the Biologics CDMO Market
Biologics CDMO Market Overview
Biologic contract development and manufacturing organisations (CDMOs) are specialised companies that provide outsourced services for the development and manufacturing of biologic drugs. These organisations support pharmaceutical and biotechnology companies in the production of biologics, which are complex molecules derived from living organisms, such as monoclonal antibodies, vaccines, cell and gene therapies, and recombinant proteins.
Biologics CDMO Market Growth Drivers
Advancements in Biologics Manufacturing Drive Global Market Expansion
The rising demand for biologics and the need for robust manufacturing infrastructure are key drivers of the market. In September 2024, Eurofins CDMO Alphora announced its plans to build a GMP biologics manufacturing facility in Mississauga, Canada, supported by federal funding and the Strategic Initiative Fund. This facility aims to enhance Canada's capacity for producing monoclonal antibodies and protein therapies for clinical and commercial use. The investment is poised to strengthen the global brain-computer interface (BCI) market by ensuring a stable supply of biologics critical for therapeutic BCI applications, enabling innovation and expanding accessibility during the forecast period.
New Biologics CDMO Ventures to Meet Biologics CDMO Market Demand
The growing demand for plasmid DNA in gene therapies and advanced biologics is shaping the CDMO market. In June 2024, Asahi Kasei Medical’s subsidiary, Bionova Scientific, announced its expansion into plasmid DNA services, establishing a dedicated facility in Texas, USA. This move aligns with the rising demand for biologics CDMOs offering specialised services. The initiative is expected to accelerate the global BCI market growth by enabling the development of cutting-edge therapies that utilise plasmid DNA, fostering innovation in neurotechnology solutions and facilitating their integration into clinical and commercial applications over the forecast period.
Biologics CDMO Market Trends
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
Rapid Expansion Driven by Rising Biologics Demand Globally
The surge in biologics development, including monoclonal antibodies and gene therapies, is driving pharmaceutical companies to outsource production to CDMOs. This trend allows companies to focus on R&D while leveraging CDMOs’ specialised capabilities, boosting market growth.
Technological Advancements Shaping Market Landscape
CDMOs are increasingly adopting single-use bioreactors and other disposable technologies to enhance production flexibility and scalability. For instance, in October 2024, Samsung Biologics, a leading contract development and manufacturing organisation (CDMO), launched a new high-concentration formulation platform, S-HiCon. This platform is designed to enhance the stability and efficacy of high-dose biopharmaceuticals, which is crucial for biologics manufacturing. Samsung Biologics is advancing its capabilities in biologics formulation, which will drive further growth in the CDMO market by supporting the development of more complex biologic drugs and ensuring their effective delivery. These innovations reduce contamination risks, improve efficiency, and cater to the needs of small and mid-scale biologics manufacturers, accelerating market development.
Investments and Facilities Expansion Elevate Biologics CDMO Market Value
Major players are making substantial investments in new manufacturing facilities to meet rising biologics demand. These expansions, particularly in emerging regions, are boosting production capacity and market value, offering tailored solutions to biopharma companies globally.
Strategic Collaborations and Regional Growth Transform CDMO Opportunities
The Asia-Pacific region is becoming a hub for biologics CDMO services, driven by lower production costs, government incentives, and growing biopharmaceutical activity. CDMOs are capitalising on this trend by establishing advanced facilities to cater to global clients.
Biologics CDMO Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Mammalian
- Non-Mammalian (Microbial)
- Biologics
- Monoclonal
- Recombinant Proteins
- Antisense and Molecular Therapy
- Vaccines
- Others
- Biosimilars
- Preclinical
- Clinical
- Commercial
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Monoclonal Antibodies Dominate Biologics CDMO Market Share Growth
The monoclonal antibodies (mAbs) segment dominates the market share by product type due to their widespread use in treating cancer, autoimmune diseases, and infectious diseases. As per the Expert Market Research analysis, the global monoclonal antibodies market is expected to grow at a CAGR of 11.5% during the forecast period of 2025-2034. Increasing demand for targeted therapies, advancements in antibody engineering, and rising approvals for biosimilar mAbs are key drivers. This segment’s robust growth potential ensures its continued market leadership, significantly driving biologics CDMO market expansion during the forecast period through innovation and scalability in production.
Biologics CDMO Market Analysis by Region
North America dominates the market due to advanced healthcare infrastructure, significant investments in biologics manufacturing, and strong R&D activity. The region benefits from a robust pharmaceutical ecosystem, regulatory support, and a focus on innovative therapies such as cell and gene therapies. Future growth is driven by rising demand for biologics and increasing outsourcing trends, positioning North America to sustain market leadership during the forecast period.
Leading Players in the Biologics CDMO Market
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Boehringer Ingelheim Group
Established in 1885 and headquartered in Ingelheim, Germany, Boehringer Ingelheim is a leading pharmaceutical company. In the biologics CDMO sector, it offers comprehensive services, including cell line development, process development, and large-scale manufacturing of therapeutic proteins and antibodies.
Wuxi Biologics (Cayman) Inc
Founded in 2010 and based in Wuxi, China, WuXi Biologics is a prominent biologics CDMO. It provides end-to-end solutions, encompassing discovery, development, and manufacturing services for biologics, including monoclonal antibodies, bispecifics, and recombinant proteins.
Samsung Biologics Co., Ltd
Established in 2011 and headquartered in Songdo, Incheon, South Korea, Samsung Biologics is a global CDMO. Its portfolio includes contract development, manufacturing, and laboratory testing services for biopharmaceutical products, focusing on monoclonal antibodies and biosimilars.
Lonza Group Ltd
Founded in 1897 and based in Basel, Switzerland, Lonza is a multinational company serving the pharmaceutical and biotechnology sectors. In the biologics CDMO market, it offers services such as cell line development, process optimisation, and large-scale manufacturing of biologics, including antibodies and cell therapies.
Other key players in the market include Fujifilm Diosynth Biotechnologies Inc., Toyobo Co. Ltd., Binex Co. Ltd, The Celonic Group, Rentschler Biopharma SE, and AGC Biologics.
Key Questions Answered in the Biologics CDMO Market
- What was the global biologics CDMO market value in 2024?
- What is the biologics CDMO market forecast outlook for 2025-2034?
- What is the market breakup based on the type?
- What is the market breakup based on product type?
- What is the market breakup based on the scale?
- What are the major factors aiding the biologics CDMO market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major biologics CDMO market trends?
- Which type will lead the market segment?
- Which product type will lead the market segment?
- Which scale will lead the market segment?
- Who are the key players involved in the biologics CDMO market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Biologics CDMO Market Overview
- 3.1 Global Biologics CDMO Market Historical Value (2018-2024)
- 3.2 Global Biologics CDMO Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Biologics CDMO Market Landscape*
- 5.1 Global Biologics CDMO Market: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Biologics CDMO Market: Product Landscape
- 5.2.1 Analysis by Type
- 5.2.2 Analysis by Product Type
- 5.2.3 Analysis by Scale
- 6 Global Biologics CDMO Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Biologics CDMO Market Segmentation (218-2034)
- 7.1 Global Biologics CDMO Market (2018-2034) by Type
- 7.1.1 Market Overview
- 7.1.2 Mammalian
- 7.1.3 Non-Mammalian (Microbial)
- 7.2 Global Biologics CDMO Market (2018-2034) by Product Type
- 7.2.1 Market Overview
- 7.2.2 Biologics
- 7.2.2.1 Monoclonal
- 7.2.2.2 Recombinant Proteins
- 7.2.2.3 Antisense and Molecular Therapy
- 7.2.2.4 Vaccines
- 7.2.2.5 Cell Therapy
- 7.2.2.6 Others
- 7.2.3 Biosimilars
- 7.3 Global Biologics CDMO Market (2018-2034) by Scale
- 7.3.1 Market Overview
- 7.3.2 Preclinical
- 7.3.3 Clinical
- 7.3.4 Commercial
- 7.4 Global Biologics CDMO Market (2018-2034) by Region
- 7.4.1 Market Overview
- 7.4.2 North America
- 7.4.3 Europe
- 7.4.4 Asia Pacific
- 7.4.5 Latin America
- 7.4.6 Middle East and Africa
- 8 North America Biologics CDMO Market (218-2034)
- 8.1 North America Biologics CDMO Market (2018-2034) by Type
- 8.1.1 Market Overview
- 8.1.2 Mammalian
- 8.1.3 Non-Mammalian (Microbial)
- 8.2 North America Biologics CDMO Market (2018-2034) by Product Type
- 8.2.1 Market Overview
- 8.2.2 Biologics
- 8.2.2.1 Monoclonal
- 8.2.2.2 Recombinant Proteins
- 8.2.2.3 Antisense and Molecular Therapy
- 8.2.2.4 Vaccines
- 8.2.2.5 Cell Therapy
- 8.2.2.6 Others
- 8.2.3 Biosimilars
- 8.3 North America Biologics CDMO Market (2018-2034) by Scale
- 8.3.1 Market Overview
- 8.3.2 Preclinical
- 8.3.3 Clinical
- 8.3.4 Commercial
- 8.4 North America Biologics CDMO Market (2018-2034) by Country
- 8.4.1 United States of America
- 8.4.2 Canada
- 9 Europe Biologics CDMO Market (218-2034)
- 9.1 Europe Biologics CDMO Market (2018-2034) by Type
- 9.1.1 Market Overview
- 9.1.2 Mammalian
- 9.1.3 Non-Mammalian (Microbial)
- 9.2 Europe Biologics CDMO Market (2018-2034) by Product Type
- 9.2.1 Market Overview
- 9.2.2 Biologics
- 9.2.2.1 Monoclonal
- 9.2.2.2 Recombinant Proteins
- 9.2.2.3 Antisense and Molecular Therapy
- 9.2.2.4 Vaccines
- 9.2.2.5 Cell Therapy
- 9.2.2.6 Others
- 9.2.3 Biosimilars
- 9.3 Europe Biologics CDMO Market (2018-2034) by Scale
- 9.3.1 Market Overview
- 9.3.2 Preclinical
- 9.3.3 Clinical
- 9.3.4 Commercial
- 9.4 Europe Biologics CDMO Market (2018-2034) by Country
- 9.4.1 United Kingdom
- 9.4.2 Germany
- 9.4.3 France
- 9.4.4 Italy
- 9.4.5 Others
- 10 Asia Pacific Biologics CDMO Market (218-2034)
- 10.1 Asia Pacific Biologics CDMO Market (2018-2034) by Type
- 10.1.1 Market Overview
- 10.1.2 Mammalian
- 10.1.3 Non-Mammalian (Microbial)
- 10.2 Asia Pacific Biologics CDMO Market (2018-2034) by Product Type
- 10.2.1 Market Overview
- 10.2.2 Biologics
- 10.2.2.1 Monoclonal
- 10.2.2.2 Recombinant Proteins
- 10.2.2.3 Antisense and Molecular Therapy
- 10.2.2.4 Vaccines
- 10.2.2.5 Cell Therapy
- 10.2.2.6 Others
- 10.2.3 Biosimilars
- 10.3 Asia Pacific Biologics CDMO Market (2018-2034) by Scale
- 10.3.1 Market Overview
- 10.3.2 Preclinical
- 10.3.3 Clinical
- 10.3.4 Commercial
- 10.4 Asia Pacific Biologics CDMO Market (2018-2034) by Country
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 ASEAN
- 10.4.5 Australia
- 10.4.6 Others
- 11 Latin America Biologics CDMO Market (218-2034)
- 11.1 Latin America Biologics CDMO Market (2018-2034) by Type
- 11.1.1 Market Overview
- 11.1.2 Mammalian
- 11.1.3 Non-Mammalian (Microbial)
- 11.2 Latin America Biologics CDMO Market (2018-2034) by Product Type
- 11.2.1 Market Overview
- 11.2.2 Biologics
- 11.2.2.1 Monoclonal
- 11.2.2.2 Recombinant Proteins
- 11.2.2.3 Antisense and Molecular Therapy
- 11.2.2.4 Vaccines
- 11.2.2.5 Cell Therapy
- 11.2.2.6 Others
- 11.2.3 Biosimilars
- 11.3 Latin America Biologics CDMO Market (2018-2034) by Scale
- 11.3.1 Market Overview
- 11.3.2 Preclinical
- 11.3.3 Clinical
- 11.3.4 Commercial
- 11.4 Latin America Biologics CDMO Market (2018-2034) by Country
- 11.4.1 Brazil
- 11.4.2 Argentina
- 11.4.3 Mexico
- 11.4.4 Others
- 12 Middle East and Africa Biologics CDMO Market (218-2034)
- 12.1 Middle East and Africa Biologics CDMO Market (2018-2034) by Type
- 12.1.1 Market Overview
- 12.1.2 Mammalian
- 12.1.3 Non-Mammalian (Microbial)
- 12.2 Middle East and Africa Biologics CDMO Market (2018-2034) by Product Type
- 12.2.1 Market Overview
- 12.2.2 Biologics
- 12.2.2.1 Monoclonal
- 12.2.2.2 Recombinant Proteins
- 12.2.2.3 Antisense and Molecular Therapy
- 12.2.2.4 Vaccines
- 12.2.2.5 Cell Therapy
- 12.2.2.6 Others
- 12.2.3 Biosimilars
- 12.3 Middle East and Africa Biologics CDMO Market (2018-2034) by Scale
- 12.3.1 Market Overview
- 12.3.2 Preclinical
- 12.3.3 Clinical
- 12.3.4 Commercial
- 12.4 Middle East and Africa Biologics CDMO Market (2018-2034) by Country
- 12.4.1 Saudi Arabia
- 12.4.2 United Arab Emirates
- 12.4.3 Nigeria
- 12.4.4 South Africa
- 12.4.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication Year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 14 Grants Analysis
- 14.1 Analysis by Year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Application
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by NIH Departments
- 14.7 Analysis by Recipient Organization
- 15 Funding and Investment Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Drug Class of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Strategic Initiatives
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Drug Class of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 Market Share Analysis, By Region (Top 5 Companies)
- 17.1.1 Market Share Analysis: Global
- 17.1.2 Market Share Analysis: North America
- 17.1.3 Market Share Analysis: Europe
- 17.1.4 Market Share Analysis: Asia Pacific
- 17.1.5 Market Share Analysis: Others
- 17.2 Boehringer Ingelheim Group
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Company News and Development
- 17.2.5 Certifications
- 17.3 Wuxi Biologics (Cayman) Inc
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Company News and Development
- 17.3.5 Certifications
- 17.4 Samsung Biologics Co., Ltd
- 17.4.1 Financial Analysis
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Company News and Development
- 17.4.5 Certifications
- 17.5 Lonza Group Ltd
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Company News and Development
- 17.5.5 Certifications
- 17.6 Fujifilm Diosynth Biotechnologies Inc.
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Company News and Development
- 17.6.5 Certifications
- 17.7 Toyobo Co. Ltd.
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Company News and Development
- 17.7.5 Certifications
- 17.8 Binex Co. Ltd
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Company News and Development
- 17.8.5 Certifications
- 17.9 The Celonic Group
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Company News and Development
- 17.9.5 Certifications
- 17.10 Rentschler Biopharma SE
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Company News and Development
- 17.10.5 Certifications
- 17.11 AGC Biologics
- 17.11.1 Financial Analysis
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Company News and Development
- 17.11.5 Certifications
- 18 Global Biologics CDMO Market – Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
